Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Cancerologie de l'Ouest
With
Poitiers University Hospital
IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA
Cyclopharma
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
histologically proven prostate adenocarcinoma
Absence of metastases (lymph node or bone)
One or more tumor nodules seen on MRI and PET Choline.
Intermediate Risk : Gleason 7 and PSA (prostate specific antigen)\<20 ng / ml, T \<T2c or Gleason 6 and PSA 10-20 ng / ml, T \<T2c
No concomitant hormonal treatment. (NB: the introduction of hormone therapy during radiotherapy before the second 18F-MISO is a criterion to study exit)
Indication of radiotherapy up to a total dose\> 70 Gy and 2 Gy/day fractions
